Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Biogen Inc (NASDAQ:BIIB)

279.81
Delayed Data
As of Jun 26
 -0.51 / -0.18%
Today’s Change
205.42
Today|||52-Week Range
307.33
+7.12%
Year-to-Date
Seeking Value in Biotech: Biogen
Jun 22 / GuruFocus News - Paid Partner Content
Nektar (NKTR) Stock Rallied Almost 50% This Year: Here's Why
Jun 16 / Zacks.com - Paid Partner Content
Pharma recovers composure as price concerns ease
Jun 21 / FT.com - Paid Partner Content
Bear of the Day: Bioverativ (BIVV)
Jun 16 / Zacks.com - Paid Partner Content
Biogen Ready for a Big Bounce
Jun 21 / TheStreet.com - Paid Partner Content
Biotech Stock Roundup: Management Changes at Biogen, Alexion, GILD Files HIV Drug
Jun 15 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: Clovis Soars on Rubraca Data, Seattle Hit by Study Halt
Jun 21 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close280.32
Today’s open281.74
Day’s range277.64 - 282.89
Volume1,279,545
Average volume (3 months)1,630,805
Market cap$59.5B
Dividend yield--
Data as of 06/26/2017

Growth & Valuation

Earnings growth (last year)+10.32%
Earnings growth (this year)+1.30%
Earnings growth (next 5 years)+5.50%
Revenue growth (last year)+9.37%
P/E ratio17.5
Price/Sales6.09
Price/Book4.99

Competitors

 Today’s
change
Today’s
% change
ILMNIllumina Inc-4.39-2.37%
GILDGilead Sciences+0.72+1.02%
BIVVBioverativ Inc-1.77-2.83%
KITEKite Pharma Inc-0.23-0.23%
Data as of 06/26/2017

Financials

Next reporting dateJuly 27, 2017
EPS forecast (this quarter)$4.54
Annual revenue (last year)$10.2B
Annual profit (last year)$3.7B
Net profit margin36.32%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Michel Vounatsos
VP-Finance, Chief Financial &
Accounting Officer
Gregory F. Covino
Corporate headquarters
Cambridge, Massachusetts

Forecasts